StemCell Therapy

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ --KlaHealth, Inc., a surgical intelligence platform that applies a dynamic cycle of patient-specific predictions, stratified interventions, and outcomes tracking to reduce surgical complications, today announced the closing of a $2.9 million Seed financing and milestone-based $10 million Series A financing led by Sant Ventures and Intuitive Ventures, and inclusive ofgrant funding from the National Science Foundation Small Business Innovation Research (SBIR) Program. These funds will accelerate the expansion of the KlaHealth platform to hospitals and surgical partners across the United States.

A Growing Need for Quality Improvement in Surgical CareIn the U.S., 51 million surgeries are performed annually, with an average complication rate of 15 percent. This results in millions of patients suffering harm and loss after a procedure. Tragically, half of these complications are known to be avoidable, and contribute to $77 billion in wasted healthcare costs each year.[1],[2]

KlaHealth helps to prevent these avoidable complications while enhancing surgical care by delivering stratified patient risk scoring. The company's state-of-the-art platform uses machine learning algorithms to match individual risk levels with graduated pathways of care that align with the unique needs of each surgical patient.

These personalized efforts bring surgery into a new era of precision medicine: with KlaHealth, surgeons can match the right patient with the right procedure with the right precautions at the right time, leading to improved patient outcomes and significant hospital savings.

The Genesis of KlaHealth KlaHealth was founded by CEO, Bora Chang, MD, and advisors Erich Huang MD, PhD, and Zhifei Sun, MD, at Duke University Health System. As practiced clinicians, all of them understood, firsthand, the unique priorities and challenges facing surgical teams.

"As a trained surgeon, I know the complexity of decision-making in caring for surgical patients," said Dr. Huang, Chief Data Officer for Quality at Duke University Health System. "We began this work because we knew that an objective, risk-based stratification tool could help providers deliver the highest levels of care."

Dr. Chang, CEO of KlaHealth added: "Our vision is to apply the lessons learned from millions of previous surgeries for the benefit of every patient undergoing a procedure. Patients and their families, clinicians, and hospitals deserve the assurance that the risks of any surgery will be safely navigated by surgical teams with the best information available to them at every point in the surgical journey. We are thrilled to have a stellar group of surgeons, hospital centers, investors, and advisors working with us to realize the opportunity of precision surgery."

Unlocking Potential Across DisciplinesTo date,KlaHealth's hospital partners have applied the company's AI-powered platform in colorectal, vascular, cardiac, and orthopedics surgical specialties.

"In our cardiac surgery department, our partnership with KlaHealth has identified up to $3 million a year in cost savings by optimizing post-procedure management for our cardiac patients," said Bruce Gewertz, MD, FACS, Surgeon-in-Chief and Chair of Surgery at Cedars-Sinai Medical Center. "Their work showcases the opportunity for improved resource utilization and data-driven clinical best practices across the surgical care continuum."

Citing colliding trends in digital health and care optimization, KlaHealth's investors emphasized the potential of the solution throughout the ecosystem of surgical care:

"KlaHealth's platform represents a powerful solution for providers and medical device partners looking to unlock the potential of data in pursuit of improved outcomes and lowering the cost of care," said Oliver Keown, MD, Director of Intuitive Ventures.

"Data-driven surgery will positively transform the way both hospitals and physicians care for patients, and we are excited to team up with KlaHealth to further innovate surgical care," added Dennis McWilliams of Sant Ventures.

About KlaHealth

KlaHealth is a healthcare data analytics company that delivers patient-specific predictive insight and risk stratification software to help improve surgical quality and prevent complications. The company was founded by a group of surgeon-scientists with a goal of harnessing machine learning algorithms to reduce patient surgical complications and improve outcomes. KlaHealth uses advanced artificial intelligence techniques to deliver a cloud-based software-as-a-service solution to healthcare providers, surgeons, and hospital systems. The company has participated in highly selective accelerator programs such as Cedars-Sinai Techstars Accelerator, Healthbox Studio, and Plug and Play. For more information about KlaHealth, visit http://www.KlaHealth.com.

About Sant Ventures

Founded in 2006, Sant Ventures is a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally-enabled healthcare services. Recent Sante successes include Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Celgene), and Explorys (IBM Corp). Sant invests nationally and is headquartered in Austin, Texas, with additional offices in Houston. For more information, please visit http://www.sante.com.

About Intuitive Ventures

Leveraging Intuitive's entrepreneurial spirit and expansive technological and clinical reach, Intuitive Ventures invests in transformative opportunities advancing positive outcomes in healthcare. The fund is focused on US and international early-stage start-ups and takes a long-term outlook to support portfolio companies reach their major milestones. Through its inaugural $100 million fund and with leadership combining decades of investing and operational experience, the team cultivates strategic resources to drive financial returns and accelerate the future of minimally invasive care. More information and future updates can be found at: http://www.intuitive-ventures.com.

[1]Dimick. J Am Coll Surg. 2004 Oct:199(4)531-7.2004.[2]Healy. JAMA Surg. 2016 Sep 1:151(9)823-30.

Contact: Elissa Baker [emailprotected]

SOURCE KlaHealth

http://www.kelahealth.com/

See the article here:
KlaHealth Raises $12.9M in Combined Seed and Series A Financing Round to Deliver AI-Powered, Clinician-Centered Solutions That Improve Surgical Care -...

MINNEAPOLIS, Oct. 27, 2020 /PRNewswire/ -- Imbio, a healthcare technology company developing the leading suite of medical image analysis for pulmonary and cardiothoracic diseases, and Siemens Healthineers, a leading medical technology company, announced they are partnering to expand access to Imbio AI algorithms worldwide. Physicians will now be able to apply Imbio's automated AI for quantitative image analysis directly through the Open Apps interface on Siemens' syngo.via platform.

Imbio provides quantitative and personalized imaging analysis for patients suffering from both acute and chronic diseases. Imbio's fully automated technology transforms chest CT studies into rich visual maps of a patient's lungs with accompanying reports that provide detailed data on the type and extent of abnormalities found in the images. For example, with Imbio Lung Density Analysis and Lung Texture Analysis clinicians can quickly visualize a patient's lungs to support diagnosis and treatment decisions for a variety of patient conditions including COPD/emphysema and fibrotic disease. Imbio products support multiple clinical initiatives such as lung cancer screening, smoking cessation and pulmonary embolism management programs, and can be used in clinical trials and academic research for numerous diseases.

"Delivering our AI solutions requires a reliable and trusted platform like syngo.via. Together with Siemens, we can now offer physicians an easily accessible and cost-effective way of testing and ultimately using our imaging AI applications without adding complexity or investments into existing hospital infrastructure. We look forward to working with Siemens Healthineers to bring our entire portfolio of products to physicians for more personalized care of patients with respiratory and cardiothoracic diseases," says Mike Hostetler, Director - Marketing and Sales at Imbio.

About ImbioImbio is a leader in fully-automated AI image analysis for acute and chronic pulmonary and cardiothoracic conditions. Imbio's solutions transform the way patients are discovered, diagnosed and treated, enabling physician productivity and more personalized care for patients. Imbio's solutions are fully automated, regulatory cleared and available through our global partners. For more information, please visit http://www.imbio.com.

About Siemens Healthineers As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology.

SOURCE Imbio

Visit link:
Imbio Partners with Siemens Healthineers to Deliver Image Analysis Tools to Clinicians Across the Globe - PRNewswire

VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ -- The globalHuman Microbiome Therapeutics Marketis forecast to be worth USD 1,098.4 Million by 2027, according to the latest analysis by Emergen Research.The human microbiome therapeutics market is forecast to augment rapidly due to the rising application of human microbiome therapeutics into personalized medicine and nutrition. Besides, the growing technological advancements in metagenomics and the therapeutic system is anticipated to further propel the market growth over the forecast timeframe.

However, huge infrastructure and equipment costs and complicated laboratory bacteria development and isolation procedures are likely to impede market growth over the forecast timeline.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/280

Key Highlights From The Report

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/human-microbiome-therapeutics-market

Emergen Research has segmented the Global Human Microbiome Therapeutics Market based on product, approach, therapeutic area, disease, and region:

Order Now: https://www.emergenresearch.com/select-license/280

Find more similar research insights by Emergen Research:

Flexible Sigmoidoscopy MarketAnalysis By Product Type (Flexible Sigmoidoscope, Rigid Sigmoidoscope), By Application (Monitoring, Diagnosis, Others), By End-User (Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Gastroenterology Institutes, Others), By Region, Forecast To 2027

Functional Fibers MarketAnalysis By Nature Type (Organic, Conventional), By Grade Type (Food-Grade, Industrial-Grade, Pharmaceutical-Grade), By Source Type (Fruits & Vegetables, Cereals & Grains, Others), By Product Type (Soluble Fibers, Insoluble Fibers), By Application (Food & Beverages, Nutraceuticals, Pharmaceuticals, Personal Care & Cosmetics, Others), By Region, Forecast To 2027

Gut Microbiome Test MarketAnalysis By Product Type (Gut Microbiome Testing Kit, Others), By Application (Homecare Settings, Hospitals, Clinics & Laboratories, Others), By Region, Forecast to 2027

Hydralazine Market Analysis By Type (Tablet, Injection), By Application (Hospital, Clinics, Diagnostic Centers, Recovery Centers, Others), By End Use, By Region, Forecast to 2027

Multiple Sclerosis Drugs MarketAnalysis By Drug Class (Immunomodulatory, Immunosuppressant, Interferon, Others), By Route of Administration (Oral, Injection), Distribution Channel (Hospital, Clinics, Retail and Online Pharmacies, Others), By Region, Forecast to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:

Eric LeeCorporate Sales SpecialistEmergen Research | Web: https://www.emergenresearch.comDirect Line: +1-(604)-757-9756E-mail: [emailprotected]

Read full Press Release at: https://www.emergenresearch.com/press-release/global-human-microbiome-therapeutics-market

SOURCE Emergen Research

View original post here:
Human Microbiome Therapeutics Market To Be Worth USD 1,098.4 Million by 2027. Key participants include: Finch Therapeutics, Biotagenics Inc., Commense...

Dublin, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The "Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blotting, Flow Cytometry), Application (Proteomics, Drug Development), End User - COVID-19 Impact - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global market projected to reach USD 14.11 billion by 2025 from USD 10.19 billion in 2020, at a CAGR of 6.7% during the forecast period.

The research antibodies and reagents market has evolved owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global research antibodies and reagents market is expected to witness significant growth in the coming years.

Based on product, the reagents segment holds the highest market share during the forecast period.

Based on product, the research antibodies and reagents market are segmented into reagent and antibodies. The reagent segment accounted for the larger market share in 2019. The reagents market is experiencing notable growth due to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields.

Based on technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period.

Based on technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. The flow cytometry segment is expected to witness the highest growth during the forecast period. This is mainly due to this technique is its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture. It offers a high throughput and the automated quantification of cell features. These factors, along with technological innovations in flow cytometry and growing cancer research, are driving the growth of this segment.

By application, the proteomics holds the highest market share during the forecast period.

Based on application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. Proteomics held the largest share of the global research antibodies and reagents market in 2019. The growth of the segment is due to as it efficiently maps drug-protein and protein-protein interactions. Moreover, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs. Proteomic technologies, such as electrophoresis, ELISA, microarrays, and MS-based proteomics, are highly efficient for analytical laboratory testing.

By end-user, the pharmaceutical & biotechnology holds the highest market share during the forecast period.

The research antibodies and reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. The pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market in 2019. The large share of this segment is attributed to the wide use of research antibodies in drug development for the identification and quantification of biomarkers and various analytical procedures.

By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025. The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also, high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Research Antibodies and Reagents: Market Overview4.2 Asia-Pacific: Research Antibodies and Reagents Market, by Application4.3 Research Antibodies and Reagents Market: Geographic Growth Opportunities4.4 Research Antibodies and Reagents Market, by Region (2018-2025)4.5 Research Antibodies and Reagents Market: Developed Vs. Developing Markets

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Increasing Research Activity and Funding for R&D5.2.1.2 Growing Industry-Academia Collaboration5.2.2 Restraints5.2.2.1 Quality Concerns and a Lack of Reproducible Results5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Personalized Medicine and Protein Therapeutics5.2.3.3 Growth in Stem Cell and Neurobiology Research5.2.3.4 Increasing Focus on Biomarker Discovery5.2.3.5 Rising Interest in Outsourcing5.2.4 Challenges5.2.4.1 Cost and Time-Intensive Antibody Development Processes5.2.4.2 Pricing Pressure Faced by Prominent Market Players

6 Industry Insights6.1 Introduction6.2 Industry Trends6.2.1 Increasing Research on Therapeutic Antibodies6.2.2 Recombinant Antibodies Are Supporting the Smooth Transition from in Vitro to in Vivo6.2.3 Growing Consolidation of the Life Science Antibodies and Reagents Market6.3 Stakeholder Analysis6.4 Strategic Benchmarking6.5 Impact of COVID-19 on the Research Antibodies and Reagents Market

7 Research Antibodies and Reagents Market, by Product7.1 Introduction7.2 Reagents7.2.1 Media & Sera7.2.1.1 Media & Sera Hold the Largest Share of the Reagents Market7.2.2 Stains & Dyes7.2.2.1 Growth of the Life Science Industry is Driving the Demand and Use of Stains & Dyes7.2.3 Fixatives7.2.3.1 Fixative Agents Are Needed to Preserve the Morphology and Antigenicity of Target Molecules7.2.4 Buffers7.2.4.1 Wide Use in Drug Development Will Drive the Market for Buffers7.2.5 Solvents7.2.5.1 Organic Solvents See Wide Use in Pharmaceutical Processes and Assays Like Ihc7.2.6 Enzymes7.2.6.1 An Increase in Proteomic and Genomic Research Activity Will Ensure Demand for Enzymes7.2.7 Probes7.2.7.1 the Versatility, Sensitivity, and Quantitative Capabilities of Probes Have Ensured Their Use in Research7.2.8 Other Reagents7.3 Antibodies7.3.1 Antibodies, by Type7.3.1.1 Primary Antibodies7.3.1.1.1 Increasing Demand for Accurate and Reliable Antibodies Follows the Rise in R&D Activity and Expenditure7.3.1.2 Secondary Antibodies7.3.1.2.1 Versatility and Low Cost of Production Have Ensured Stable Growth in the Market for Secondary Antibodies7.3.2 Antibodies, by Form7.3.2.1 Monoclonal Antibodies7.3.2.1.1 Monoclonal Antibodies Are Among the Most Common Tools in Biomedical Science7.3.2.2 Polyclonal Antibodies7.3.2.2.1 Thermo Fisher Scientific and Abcam Are Major Players in the Polyclonal Antibodies Market7.3.2.3 Recombinant Antibodies7.3.2.3.1 Recombinant Antibodies Provide a High-Specificity, High-Sensitivity Option7.3.3 Antibodies, by Source7.3.3.1 Mice7.3.3.1.1 Mice Are the Preferred Hosts for Research-Use Antibody Production7.3.3.2 Rabbits7.3.3.2.1 Rabbits Are a Cost-Effective Means of Antibody Production7.3.3.3 Other Sources7.3.4 Antibodies, by Research Area7.3.4.1 Oncology7.3.4.1.1 the High Prevalence of Cancer Has Boosted Research Activity in the Sector7.3.4.2 Infectious Diseases7.3.4.2.1 Rising Awareness and Growing Research Activity Are Key Drivers of the Market7.3.4.3 Immunology7.3.4.3.1 Antibodies Are Used to Identify Protein and Peptides to Understand Infectious Disease Immunology Better7.3.4.4 Neurobiology7.3.4.4.1 Antibody-Based Approaches Are Widely Used in Molecular and Cellular Neuroscience7.3.4.5 Stem Cells7.3.4.5.1 Increasing Funding and the Growing Importance of Stem Cells in Transplantation Are Key Market Drivers7.3.4.6 Other Research Areas

8 Research Antibodies and Reagents Market, by Technology8.1 Introduction8.2 Western Blotting8.2.1 High Accuracy, Ease of Interpretation, and Other Advantages Have Propelled the Use of Western Blotting8.3 Flow Cytometry8.3.1 Flow Cytometry is the Fastest-Growing Technology Segment of the Market8.4 Enzyme-Linked Immunosorbent Assay8.4.1 Elisa Has the Potential to Supersede the Current Gold Standard for COVID-19 Testing8.5 Immunohistochemistry8.5.1 Complexities of Ihc Pose Challenges to Market Growth8.6 Immunofluorescence8.6.1 Immunofluorescence Helps Determine Specific Gene Expressions8.7 Immunoprecipitation8.7.1 Results Obtained by Ip Can be Analyzed Through Other Technologies8.8 Other Technologies

9 Research Antibodies and Reagents Market, by Application9.1 Introduction9.2 Proteomics9.2.1 Proteomics Holds the Largest Share of the Market, by Application9.3 Drug Development9.3.1 the Drug Development Applications Segment is Expected to Grow at the Highest Rate9.4 Genomics9.4.1 Genomics is Currently An Emerging Area of Research Applications and Expected to See Growth in the Coming Years

10 Research Antibodies and Reagents Market, by End-user10.1 Introduction10.2 Pharmaceutical & Biotechnology Companies10.2.1 Pharma & Biotech Companies Dominate the End-User Market10.3 Academic & Research Institutions10.3.1 Growing Government Investments to Propel the Market10.4 Contract Research Organizations10.4.1 Growing Work on Monoclonal Antibodies and Drug Conjugates Among Cros is Aiding Market Growth

11 Research Antibodies and Reagents Market, by Region11.1 Introduction11.2 North America11.3 Europe11.4 Asia-Pacific11.5 Latin America11.6 Middle East and Africa

12 Competitive Landscape12.1 Overview12.2 Matrix Evaluation Framework12.3 Research Antibodies Market Share Analysis12.4 Competitive Leadership Mapping12.4.1 Stars12.4.2 Emerging Leaders12.4.3 Pervasive Companies12.4.4 Emerging Companies12.5 Competitive Situation and Trends12.5.1 Product Launches12.5.2 Expansions12.5.3 Acquisitions12.5.4 Collaborations, Partnerships, and Agreements

13 Company Profiles13.1 Thermo Fisher Scientific13.2 Merck Group13.3 Abcam plc13.4 Becton, Dickinson and Company13.5 Cell Signaling Technology13.6 Bio-Rad Laboratories13.7 F. Hoffmann-La Roche13.8 Agilent Technologies13.9 Danaher Corporation13.10 Lonza13.11 Genscript13.12 PerkinElmer13.13 Biolegend13.14 Illumina13.15 Immunoprecise Antibodies13.16 Fujirebio Diagnostics Ab13.17 Analytik Jena Ag13.18 Omega Bio-Tek13.19 Dovetail Genomics13.20 Atlas Antibodies

14 Appendix14.1 Insights of Industry Experts14.2 Discussion Guide14.3 Knowledge Store: Subscription Portal14.4 Available Customizations14.5 Related Reports14.6 Author Details

For more information about this report visit https://www.researchandmarkets.com/r/h35zte

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
COVID-19 Impact on the Research Antibodies & Reagents Market by Product, Technology, Application, End-user - Global Forecast to 2025 -...

Breast cancer is the most commonly occurring cancer for women around the world, and much effort has been spent in the development of therapies to treat this disease. Among these treatments, chemotherapy has been shown to be among the most effective methods; however, the drugs used in these therapies can have adverse side effects, the most serious of which is toxicity to the heart. In addition to tissue damage to the heart, chemotherapeutic breast cancer drugs can also affect the heart's pumping ability or result in clinical heart failure.

In order to avoid these problems, efforts are made to monitor the heart of patients who are undergoing chemotherapeutic treatment for breast cancer and to adjust their treatment levels accordingly. Current methods to monitor the heart include the use of echocardiograms and other imaging procedures, as well as taking biopsies of the heart. But the imaging methods only detect late-stage, irreversible cardiac failure and biopsies are highly invasive and are physically painful for the patient.

There are alternative monitoring systems that can be created in the laboratory to mimic what is happening in the body. These organs-on-a-chip models consist of a silicone chip with compartments for culturing specific types of live human tissues. The compartments are connected to microfluidic channels through which oxygen and nutrient media are pumped and circulated. The tissue cells normally secrete molecules called biomarkers into the surrounding medium, which are good indicators of their health and function. The levels of these biomarkers can then be measured in order to determine the condition of the tissues.

Recently, methods have been successful in creating simple systems to monitor heart toxicity from breast cancer drugs in selected patients, but, to date, there have been few attempts to produce such a system in a larger, more comprehensive and reliable model.

A collaborative team, which includes a group from the Terasaki Institute for Biomedical Innovation, has developed an organs-on-a-chip system that more widely examines the responses of breast cancer and heart tissues to therapeutic breast cancer drugs. For their system, they chose to measure two cardiac biomarkers which are produced by healthy heart cells and one biomarker that is produced by actively growing breast cancer cells. Included in the study were tests of both healthy and artificially-induced damaged heart tissues, to mirror the possible heart conditions of breast cancer patients prior to chemotherapy. They also devised added features to the system to enhance its capabilities.

The team designed a chip system with two separate compartments for tissue cultures of breast cancer and either healthy or artificially-induced damaged heart tissues; these compartments were connected by channels which allowed the free flow of fluid between them. To more closely reproduce the mechanical properties of native body tissues, the tissue cultures were prepared by enclosing tiny spheroids of either heart or breast cancer cells in a gelatinous substance. Pre-determined controls for the chip's circulatory fluidic system ensured that the tissues received oxygen, nutrient media and chemotherapeutic drug delivery.

"This work establishes an important model for monitoring cardiac toxicity from breast cancer chemotherapy," said first author Junmin Lee, Ph.D., part of the Terasaki Institute's research team. "We successfully created cardiac and breast cancer tissues that closely mimic bodily tissues, and we developed an improved sensing device and drug delivery system; these are milestones in organs-on-a-chip technology."

In comparison with single-compartment models with either heart or breast cancer tissues, it was found that actively growing breast cancer tissues in communication with heart tissues decreased the levels of healthy heart biomarkers than those found in the single-chip systems. Moreover, the dual-chip system provided evidence that the breast cancer cells' biomarker secretion was affected not only by drug treatment, but by their interaction with cardiac tissues with different levels of damage. This showed that the interplay between the heart and breast cancer tissues had an important influence on indicators of cell function and disease progression.

Although no definitive conclusions could be made on whether pre-damaged heart tissues were more susceptible to cardiac injury when exposed to breast cancer drugs, the results showed that in healthy cardiac tissues, delivery of the breast cancer drug resulted in decreased cellular growth and secretion of healthy heart biomarkers than without the drug.

Further tests may be conducted to explore the use of this model for detecting and predicting cardiac toxicity from chemotherapeutic drugs. The model may be expanded to include observations of tissues cultured on a long-term basis, examination of additional biomarkers, testing the model using tissues derived from several patients and measurements of other, non-biomarker indicators of cardiac damage (electrical and contractive functions, for example). Future possibilities could be the addition of a liver tissue component onto the chip and considerations of the system's scalability to correlate with bodily systems.

"These efforts lay important groundwork that can pave the way to future applications in disease modeling," said Ali Khademhosseini, Ph.D., director and CEO for the Terasaki Institute. "The Personalized Physiological platform that we have at our Institute is one of the many vehicles that we have for bringing personalized medicine to the real world."

Reference:Lee J, Mehrotra S, Zare-Eelanjegh E, et al. A heart-breast cancer-on-a-chip platform for disease modeling and monitoring of cardiotoxicity induced by cancer chemotherapy. Small. 2020;2004258. doi:10.1002/smll.202004258

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
HeartBreast Cancer-on-a-Chip Developed To Monitor Cardiac Toxicity Arising From Chemo - Technology Networks

Global Biobanks Market: Snapshot

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=2321<ype=S

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks instem cellresearch has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See the original post:
Biobanks Market Analysis Growth Opportunities and Trends by Forecast To 2025 - The Think Curiouser

DNA sequencing is a molecular technique that helps to determine the nucleotide sequence of deoxyribonucleic acid (DNA), which is the fundamental unit of a gene or genome. DNA sequencing has led to a paradigm shift in molecular biology and genomics sectors. The knowledge of DNA sequences of genes and other parts of the genome of organisms has gained prominence in life science research as well as in applied fields, such as forensics, cancer diagnostics, and others. DNA sequencing is used for sequencing DNA strands and whole genomes as well as to study various DNAprotein interactions. Moreover, this technique enables researchers to focus, study, and interpret deep sequence target regions.

Furthermore, it is utilized in various interventions such as oncology, biomarker studies, drug discovery, reproductive health, and personalized genomics. The growth of the global DNA sequencing market is driven by technological advancements in sequencing equipment, surge in applications of DNA sequencing, and increase in genome mapping programs. In addition, rise in awareness pertaining to DNA sequencing and increase in investment in research, development, and innovation have supplemented the market growth. However, dearth of skilled professionals, ethical & legal limitations related to DNA sequencing, and standardization concerns in sequencing procedures impede the market growth.

Based on product, the consumable segment acquired the largest North America DNA sequencing market share in 2018 and constitute a dominant share in 2025 due to the use and necessity in sample preparation and in pre-requisite stages of DNA sequencing. The biomarker and cancer segment is the highest contributor to the North America DNA sequencing as a result of technological advancements and increase in DNA sequencing applications. The personalized medicine segment is anticipated to be a lucrative segment owing to the rise in use of precision medicine wherein the treatment takes in account the individuals variation in the genes, lifestyle and environment. Therefore, these factors contribute toward the growth of the North American DNA sequencing market.

According to technology, the sequencing by synthesis segment was the highest contributor to the North America DNA sequencing market owing to the wide use of DNA sequencing platforms in sequencing protocols and is likely to continue the dominance throughout the forecasting period. Moreover, the research institute segment was the highest contributor to the North America DNA sequencing in 2018 and is occupying the largest share in the North American DNA sequencing market due to the presence of large number of research centers in this region and ongoing research.

In 2018, U.S. occupied the largest share of the North America DNA sequencing market and is expected to maintain its dominance during the forecast period owing to the presence of DNA sequencing giants in this region and the rising incidences of genetic disorders and cancers amongst the population. On the other side, Mexico is estimated to register the fastest growth during the forecast period.

KEY FINDINGS OF THE STUDY-

The pediatrics segment accounted for more than half of the market share in 2018. U.S. and Canada collectively accounted major share of the North America DNA sequencing market in 2018 and is expected to maintain this trend throughout the forecast period. The pharmaceutical company in the end user segment is anticipated to grow at a high CAGR from 2018 to 2025. The biomarker and cancer segment accounted major able share of the market in 2018.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:support@researchdive.comLinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Read more from the original source:
Advancement: Know the Rapid Growth Factors of North America DNA Sequencing Market| Stay Up-To-Date With Emerging Trends Ahead - re:Jerusalem

Vascular endothelial growth factor-directed therapies play a significant role in patients with metastatic renal cell carcinoma (mRCC). Biomarkers for predicting treatment efficacy and resistance are required to develop personalized medicine. We evaluated multiple serum cytokine levels in patients with mRCC treated with axitinib to explore predictive biomarkers.

From September 2012 to October 2015, serum samples were collected from 44 patients with mRCC before treatment and 4weeks after axitinib initiation. Bio-Plex Pro Human Cancer Biomarker Panels 1 and 2 were used to measure levels of 34 serum biomarkers related to angiogenesis and cell proliferation.

Patients with partial response or stable disease had significantly decreased serum plasminogen activator inhibitor-1 (PAI-1) level from pre-treatment to 4weeks after axitinib initiation compared with those with progressive disease (P = .022). The median progression-free survival (PFS) and median overall survival (OS) in patients with increased serum PAI-1 level from pre-treatment to 4weeks after axitinib initiation were significantly shorter than those with decreased serum PAI-1 level (P = .027 and P = .026, respectively). Increased serum PAI-1 level from pre-treatment to 4weeks after axitinib initiation was an independent prognostic marker for shorter PFS and OS in multivariate analyses (P = .015 and P = .032, respectively). The immunohistochemical staining intensity of PAI-1 in tumor specimens was significantly associated with Fuhrman grade and presence of distant metastasis (P = .026 and P = .010, respectively).

The initial change in serum PAI-1 level in the early stage of axitinib treatment could be a useful prognostic biomarker in patients with mRCC.

Health science reports. 2020 Oct 15*** epublish ***

Naoko Honma, Takamitsu Inoue, Norihiko Tsuchiya, Atsushi Koizumi, Ryohei Yamamoto, Taketoshi Nara, Sohei Kanda, Mingguo Huang, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Shigeru Satoh, Tomonori Habuchi

Department of Urology Akita University Graduate School of Medicine Akita Japan., Center for Kidney Disease and Transplantation Akita University Hospital Akita Japan.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33088925

Continue reading here:
Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell...

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive is pleased to announce it has partnered with The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers to host the 11th Annual Ruesch Center Symposium Nov. 20-21.

We are honored to be able to work with The Ruesch Center to help transition their annual symposium into a virtual, interactive learning experience during this uncertain time, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of OncLive. The Ruesch Center is part of our exclusive strategic alliance partnership program, and this is a great example of how we can use our state-of-the-art studio to still deliver critical information to the gastrointestinal cancer community.

The educational symposium brings together clinicians, researchers, patients, caregivers, policymakers and industry representatives to network and debate critical issues related to GI cancers. Throughout the two-day virtual meeting, expert speakers will participate in three educational sessions addressing topics such as innovations in therapeutics, cancer genetics and targeted therapies, nuclear imaging and therapy for neuroendocrine tumors, and precision medicine.

The sessions include the following:

As a special highlight, the symposium will offer access to watch the 2020 Luminary Awards in GI Cancers ceremony. The five honorees, Richard M. Goldberg, M.D.; Gayle S. Jameson, MSN, RN, ACNP-BC, AOCN; Stacie C. Lindsey; Tyvin Rich, M.D., FACR; and Diane M. Simeone, M.D., will be presented with their awards and honored for their dedication to improving care for patients and families who are affected by GI cancers.

Finding more cures for GI cancer will only come through innovative research, and we are so proud to be featuring both the most up-to-date science and the projects of tomorrow. And as a bonus, we will be premiering our new POWER program, a short course in precision medicine to close our knowledge gaps in this rapidly evolving field, said John L. Marshall, M.D., director, The Ruesch Center for the Cure of GI Cancers.

This symposium has been approved for up to 11 AMA PRA Category 1 Credits and ANCC contact hours.

For more information and to register, click here.

About OncLive

A digital platform of resources for practicing oncologists, OncLive offers oncology professionals information they can use to help provide the best patient care. OncLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About The Ruesch Center for the Cure of Gastrointestinal Cancers

The Ruesch Center for the Cure of Gastrointestinal Cancers is part of the Georgetown Lombardi Comprehensive Cancer Center. It focuses on personalized patient care and fighting against gastrointestinal cancers. The Ruesch Center provides the highest standard of care and individualized cures through clinical trials and research, education and advocacy, and regional and global alliances.

Go here to read the rest:
OncLive Partners with The Ruesch Center to Host the 11th Annual Ruesch Center Symposium - Business Wire

The NIH Strategic plan focuses on "Precision Nutrition What to Eat to Stay Healthy." NIH in conjunction with the Nutrition Research Task Force will partner with private and public organizations to accelerate nutrition science with the focus on precision medicine. The ambitious initiative looks to push forward the concept of individualized dietary recommendations to maximize health as well as prevent and combat disease.

"We are thrilled to be recognized by NIH as a pioneer in the field of precision nutrition. We look forward to supporting and participating in the ongoing research effort toward new discoveries," said Lihi Segal, CEO and founder of DayTwo.

Metabolic disease (diabetes, prediabetes, clinical obesity and NASH) impacts almost 3/4 of U.S. adults and costs the U.S. economy almost $700 billion a year. In the era of COVID-19, people with diabetes rank first and second at risk for hospitalizations and death if they contract the disease. Poor nutrition is a root cause of metabolic disease and according to the American Diabetes Association, food choices are the greatest stressor and have the greatest impact on daily life for people with diabetes.

DayTwo was founded as a result of a clinical trial published in Cell in 2015 entitled, "Personalized Nutrition by Prediction of Glycemic Responses." A follow-up clinical trial was published in the Journal of the American Medical Association in 2019 entitled, "Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food." Both studies demonstrated that people respond differently to the same food, and the personalized response can be predicted using machine learning algorithms based on high resolution, gut microbiome profiling and additional clinical and personal parameters.

Employers and payers looking to learn more can contact Robert Boyer, vice president of Enterprise Solutions, at [emailprotected]. Or, visit http://www.daytwo.com/employers.

About DayTwo DayTwo is the only precision nutrition solution that enables a path to remission for metabolic disease. DayTwo's telehealth-centric, high touch / high tech solution employs machine learning algorithms based high resolution gut microbiome profiling and additional clinical and personal parameters, a care team of Certified Diabetes Care and Educational Specialists / Registered Dietitian Nutritionists skilled in behavioral coaching and a digital app to achieve outcomes. DayTwo offers up to 100% fees at risk for its solution.

For questions or comments about this release please contact [emailprotected] 415-426-4767.

SOURCE DayTwo

https://www.daytwo.com

Go here to read the rest:
DayTwo Science Cited in 10-Year $150 Million National Institutes of Health Precision Nutrition Strategic Plan - PRNewswire

COVID-19 has led to rapid changes in health care innovation: telemedicine, artificial intelligence, payment models, and a host of other digital analytics tools have morphed from experimental to borderline conventional.

At a panel during the 2020 North Texas State of Reform Virtual Health Policy Conference, health executives Tom Banning, chief executive officer of Texas Academy of Family Physicians,Dr. Andrew Masica, senior vice president of Texas Health Resources, and Dr. Steve Miff, president of Parkland Center for Clinical Innovation, met to discuss which of these developments will last beyond the pandemic.

Before COVID-19, telemedicine accounted for about one percent of health care visits, approximately 1.4 million visits. According to Tom Banning, seven months later, the nation has seen a three-fold increase in the use of telemedicine, accounting for about 35 million virtual visits.

I dont think theres any question that telemedicine is here to stay, Banning says. Its proven its effectiveness. Patients now expect to be able to connect with their doctors, and doctors see value in connecting with their patients.

Despite the high reliance on telehealth during the pandemic, health executives like Banning acknowledge that there are still workflow and payment methodologies to develop for telemedicine to become a scalable and viable innovation long term.

I dont think theres any question that telemedicine is here to stay.

Through partnerships and collaboration across healthcare organizations, leaders have rapidly applied predictive analytics to engage with the surrounding community.Its kind of ironic. Data and computers are helping deliver more personalized medicine, Dr. Andrew Masica says. If we do it the right way, thats a possibility for health systems.

The pandemic laid bare the need for high-speed data reports that allow primary care physicians to understand and digest patient information quickly. Through this innovation, healthcare providers and physicians can better leverage data, creating more personal interactions with patients.

There has been a paradigm shift, Masica says. We know the market and patient expectations are going to be different. Our challenge is to adapt to whats at hand. The underlying theme of where digital tools and innovation can help us is the push towards a more consumer and patient-centered health system with the ability to leverage data in real-time.

The development of proximity data has been crucial to understanding the viruss spread and defining vulnerability indexes. Initially, health officials attempted to track the virus by monitoring Americans international travel. With the virus rapid spread across the nation and relatively high case counts months later, these data tools have provided health experts with predictive tools to anticipate the virus and critical areas of concern.

It gives us something very actionable to do, Dr. Miff says. Predictive modeling is pretty simple. Based on a patients address, we can geo-map every single positive case, and then use a sophisticated machine learning formula to calculate distances to those positive cases and the density.

As the industry adapts to changes in innovation, health leaders are regularly evaluating the outcomes of these new measures to determine their effectiveness outside of controlled trials. Moving beyond the pandemics initial peak, further study will be necessary for defining these tools future use.Proof of efficacy isnt proof of effectiveness, Masica says. We need to be adopting and pushing digital innovations that are shown to be effective and rigorously assessing the outcomes of these technologies.

See the original post:
COVID-19 Is Redefining Healthcare Innovation - D Healthcare Daily

The patient-physician relationship, foundational to the profession of medicine and healing, relies on open and honest dialogue and an unwavering trust that we are making decisions about our patients health and livelihoods free of undue influence or conflicts of interest. The same is true for our public health institutions and our health system at largeespecially in a time of great urgency and crisis.

During this COVID-19 pandemic, physicians are unfortunately fighting a two-front war. Already facing one of the greatest threats to public health in generations, we have been pulled into a public battle we did not want over the very legitimacy of our work and our motivation.

The assault on public health and the undermining of efforts to defeat COVID-19 began with unfounded suspicions about the science and evidence of this novel coronavirus and how it spreads. It grew with speculation about harmful and unproven treatments for COVID-19, false claims that masks were a source of infections, and by misleading suggestions that increased testing alone explains why case counts are surging.

It expanded again with inaccurate, dangerous statements about children being almost immune from the most serious effects of COVID-19, a reckless plan of focused protection and naturally acquired herd immunity as a pathway out of this pandemic, and most recently with wild and highly offensive claims that physicians are inflating the number of COVID-19 cases and deaths to increase our incomes.

At every turn, at the highest levels of government, our motives and efforts are undermined, questioned and discredited in a misguided attempt to downplay the seriousness of the pandemic we continue to fight.

Many physicians, nurses and other health care personnel have died, and many more have fallen ill, while treating our patients. Public health officials have been threatened and intimidated, prompting some to retire or quit critical positions. All have worked tirelessly and under considerable stress and strain to turn the tide against COVID-19. We know these numbers surely will grow in the weeks ahead as the accelerating pace of this pandemic places enormous pressure on our already crowded hospitals and front-line physicians and first responders.

A continued campaign of misinformation and disinformation at this urgent hour is an unconscionable betrayal of the public trust that jeopardizes our work and endangers lives.

The U.S. is rapidly approaching 9 million confirmed cases of COVID-19, far surpassing every other country on earth. More than 225,000 of our fellow citizens have died and thousands more cling to life in crowded intensive care units across the country as cases surge ever higher.

Soon we will enter another critical period of this pandemic, a time when we will ask the public to trust the work of scientists, researchers and physicians, and get vaccinated against this virus.

A safe and effective COVID-19 vaccine will be a remarkable feat, and a true turning point in the pandemic. The language we use about this accelerated process and the checks and balances meant to ensure safety and efficacy is critical. We cannot afford to lose the faith of our patients. Not when so much death and suffering has already occurred. Not when physiciansand our entire health care communityhave already paid so steep a price.

Our AMA will always stand on the side of patients and physicians, of science and evidence, and of free and honest conversations that build the trust that is so crucial to our work. We will not hesitate to call out political intimidation and fear-driven rhetoric that undermines this trust or that interferes with our ability to deliver the very best care to patients.

Anything less is a rejection of the oath we take as physicians, and of the ethical principles that guide our profession.

More here:
The assault on physicians and science must end - American Medical Association

Study Demonstrates Superior Performance of ThyGeNEXT and ThyraMIR vs. Other Molecular Tests

PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled Multiplatform molecular test performance in indeterminate thyroid nodules was published on-line in the peer-reviewed journal, Diagnostic Cytopathology. This paper represents the culmination of a multi-center, blinded clinical validation study in which gold standard unanimous histopathology consensus diagnosis was utilized. The study results demonstrate that ThyGeNEXT + ThyraMIR combination testing yield the highest positive predictive value (PPV) and similar negative predictive value (NPV) in comparison to other marketed tests for the same indication.

Approximately 25% of thyroid nodule fine needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Ancillary multiplatform testing with ThyGeNEXT and ThyraMIR assists in the accurate risk stratification of these FNAs, ultimately helping to distinguish patients who are more likely to benefit from conservative management from those who are more likely to benefit from surgical intervention.

The published manuscript is the first to report the performance characteristics of combination ThyGeNEXT and ThyraMIR testing in a blinded multicenter study. ThyGeNEXT is the companys most recent next generation sequencing based test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer. The study demonstrates that combination testing with ThyGeNEXT and ThyraMIR has both high sensitivity (95%) and high specificity (90%) for identifying disease. It also highlights the important role that ThyraMIRthe companys proprietary microRNA risk classifiercan play in helping to identify malignancy in nodules where single platform mutation panels commonly detect mutations that by themselves have suboptimal PPV for malignancy.

According to Jack Stover, President and CEO of Interpace, The results of this independent study reported in a well-respected journal reflect the strong clinical performance and overall value of our combined thyroid assays in helping physicians manage their patients with potential thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT is Interpaces most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and most Commercial insurers.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor RelationsEdison Group Joseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com/ mpaul@edisongroup.com

Here is the original post:
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays - GlobeNewswire

Global DNA Sequencing Market Report Covers Market Dynamics, Market Value Chain, And Future Prospective

DNA Sequencing marketis experiencing a growth that the global industry has never-ever seen before. The considerable growth and development are basically due to the current increasing demand and supply on the global platform. The current market dossier provides the necessary details such as the monetary fluctuations, industrial trade, future scopes, and global market status in a smooth-tongued pattern.

The DNA Sequencing market report has some of the major players Abbott Laboratories, ZS Genetics, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, 454 Life Sciences Corporation (Roche Holding AG), Beckman Coulter (Fullerton, CA), BGI, Illumina, Pacific Biosciences of California, Inc., Siemens AG, F. Hoffmann-La Roche, LI-COR, Inc., Pacific Biosciences of California leading the current global market mentioned. The research report has all the vital details about the past, present, and future aspects of the DNA Sequencing market mentioned with great transparency.

Click here for the free sample copy of the DNA Sequencing Market report

An Overview About the Table of Contents:

Global DNA Sequencing Market Overview Target Audience for the DNA Sequencing Market Economic Impact on the DNA Sequencing Market Global DNA Sequencing Market Forecast Business Competition by Manufacturers Production, Revenue (Value) by Region Production, Revenue (Value), Price Trend by Type Market Analysis by Application Cost Analysis Industrial Chain, Sourcing Strategy, and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis

In the global market, there is always a tough competition going on between the various players so as to top the chart. The current DNA Sequencing market seems to have succeeded in sowing its seed of success and is enjoying the benefits of the reaping taking place on a global platform. The most important aspect provided in the report is the variation in the financial scale that can give the clients a complete idea about the current monetary gain and loss. The geographical segmentation North America (United States, Canada and Mexico), Europe (Germany, UK, France, Italy, Russia and Turkey etc.), Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) gives the readers an entire data about the growth and development taking place across the world. The informative report also presents some data based on the market bifurcations, growth factors, futuristic aspects, industrial policies, and product supply and demand for a better piece of understanding.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-dna-sequencing-market-report-2020-by-key-players-71362.html

Key Insights encompassed in the DNA Sequencing market report

Latest technological advancement in the DNA Sequencing market Studying pricing analysis and market strategies trailed by the market players to enhance global DNA Sequencing market growth Regional development status off the DNA Sequencing market and the impact of COVID-19 in different regions Detailing of the supply-demand chain, market valuation, drivers, and more

One of the vital data mentioned in the report includes that of the overall market segmentation based on the product type, applications, end-users, and various other subtypes. The market segmentation {Semiconductor Sequencing, Pyrosequencing, Sequencing by Synthesis, Single-Molecule Real-Time Sequencing (SMRT), Sequencing by Ligation (SBL), Others}; {Diagnostic, Drug Discovery, Biomarker Discovery, Personalized Medicine, Others} helps the clients and other readers obtain a crystal-clear context about the DNA Sequencing market. The knowledgeable aspects mentioned in the current scientific report is made available at the tip of the finger with just a click.

Questions answered by the DNA Sequencing market report:

Which are regions witnessing the highest growth during the forecast period? How the surging prices of raw materials will affect the growth of the DNA Sequencing market? Which are major market players? How are the market players intensifying their global presence? If yes, how? What are the key strategies used by the market players to improve their market position post the COVID-19 pandemic?

Enquire Here Get customization & check discount for report@https://www.marketdataanalytics.biz/global-dna-sequencing-market-report-2020-by-key-players-71362.html#inquiry-for-buying

Why Choose Market Data Analytics reports?

Our analysts use latest market research techniques to create the report Market reports are curated using the latest market research and analytical tools Customization of report is possible as per the requirement Our team comprises of expertise and highly trained analysts Quick responsive customer support for domestic and international clients

Read the rest here:
Global DNA Sequencing Market 2020 COVID-19 Updated Analysis By Product (Semiconductor Sequencing, Pyrosequencing, Sequencing by Synthesis,...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community. The program seeks to shine a light upon unsung community heroes who often go unrecognized by traditional awards programs and this year saw nominations from 31 states.

The pace at which oncology care is progressing is both rapid and extraordinary, said Chatrick Paul, Head of US Oncology, AstraZeneca. We know that coming together as a community is essential to advancing cancer care and realizing meaningful change for cancer patients. This could not be more true than now when COVID-19 has disrupted efforts of the healthcare community to screen, test and diagnose cancer patients in a timely manner. We know that together, through this program, we can remove barriers to care, transform health systems and support patients beyond our medicines.

Cancer impacts millions of Americans and is something no one should ever have to experience alone, said Jeremy Abbate, Publisher, Scientific American Custom Media. This years winners and finalists collectively embody the sentiment and purpose of the C2 Awards. We are humbled to share their heartfelt stories of dedication and sacrifice to instill new hope for those across our country facing a cancer diagnosis.

The C2 Awards feature four categories, recognizing the community in the following ways: extending quality care to underserved communities, improving the patient experience, advancing precision medicine and doing something tangible and inspiring for patients. Winners will each receive $50,000 donation to pay forward to a non-profit organization serving the cancer community.

The 2020 Cancer Community Awards Recipients

The C2 Catalyst for Change award celebrates those who significantly improve access to cancer care for underserved populations.

The C2 Catalyst for Care award recognizes those who enhance the experience of care for patients during their cancer treatment.

The C2 Catalyst for Precision Medicine award honors those who improve personalized treatment for cancer patients.

The Presidents Award, selected by AstraZeneca, honors those who make a tangible and inspiring difference for patients and their loved ones.

Nominations were evaluated by an esteemed panel of multidisciplinary community leaders, including Edward Abrahams, PhD, President, Personalized Medicine Coalition; Meghan Gutierrez, CEO, Lymphoma Research Foundation; Erin McAllister, formerly at BioCentury; Audra Moran, President & CEO, Ovarian Cancer Research Alliance; Dr Barbara Gitlitz, MD, Medical Oncologist, Keck School of Medicine of USC; Dr Geoffrey Oxnard, MD, Thoracic Oncologist, Dana-Farber Cancer Institute; Dr Keith Winfrey, MD, MPH, Chief Medical Officer, New Orleans East Louisiana Community Health Center; and Leah Fine, Director, Centers of Excellence Program, GO2 Foundation for Lung Cancer.

More details on finalists and winners can be found here.

About YOUR Cancer

The C2 Awards are part of the YOUR Cancer Program, a broader initiative launched by AstraZeneca to spotlight those at the forefront of cancer research and patient support who are contributing toward eliminating cancer as a cause of death. YOUR CANCER aims to convene, engage, and highlight the full breadth of the oncology community, utilizing four pillars: a digital partnership hub profiling community resources and perspectives, an awards program recognizing the unsung heroes of oncology, state-level roundtables with local policymakers and advocates, and media and speaking engagements profiling community oncology leaders.

About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients lives and the Companys future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in hematology.

By harnessing the power of four scientific platforms Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

About Scientific American Custom Media

Scientific American's award-winning Custom Media team (SACM) develops targeted, strategic content programs in partnership with corporations, governments, and academic institutions. SACM operates as a division separate from the magazines Board of Editors to create highly engaging, one-of-a-kind media programs for thought-leading audiences. From mini-documentaries or custom events to standalone magazines and native content series, SACM offers its partners opportunities to build compelling and distinct narratives that convey their brand values and unique stories.

See more here:
AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards - Business Wire

The global artificial intelligence (AI) in medicine market was valued at $719 million in 2017 and is estimated to reach $18,119 million at a CAGR of 49.6% from 2018 to 2025. AI is an intelligent system that applies various human intelligence-based functions such as reasoning, learning, and problem-solving skills. AI technology uses software and different algorithms in the field of pharmaceuticals to support the decision-making processes for existing drugs and repurposing drugs to treat other conditions, along with accelerating the clinical trials process by finding the right patients from several data sources.

Major Key Players of the Artificial Intelligence in Medicine Market are:InSilico Medicine, Globavir Biosciences, GNS Healthcare, Flatiron Health, Benevolent AI, Atomwise, Verge Genomics, Cloud Pharmaceuticals, and Recursion Pharmaceuticals.

Get sample copy of Artificial Intelligence in Medicine Market at:http://bit.ly/38ISZeC

Shortage of skilled healthcare professionals and increase in the processing power of AI systems that is projected to help improve the efficiency of drug discovery and management of clinical trials majorly drive the growth of the global artificial intelligence in medicine market. Furthermore, the growth in importance of precision medicine and rise in funding of the R&D activities for the use of AI technology in the field of medicine are expected to fuel the market growth. However, limited acceptance from healthcare professionals and limitations of AI decision-making can impede the market growth. Untapped market opportunities available in developing regions such as India and China help to open new avenues for the growth of the artificial intelligence in medicine market in future.

The global artificial intelligence in medicine market is segmented based on product type, technology, application, and region. Based on product type, the market is segmented into hardware, software, and service. Based on technology, the market is classified into deep learning, querying method, natural language processing, and context aware processing. Based on application, the market is categorized into drug discovery & repurposing, clinical research trial, personalized medicine, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major Types of Artificial Intelligence in Medicine Market covered are:Deep Learning, Querying MethodNatural Language ProcessingContext Aware Processing

Major Applications of Artificial Intelligence in Medicine Market covered are:Drug Discovery & RepurposingClinical Research TrialPersonalized Medicine, and Others

Research objectives:-

To study and analyze the global Artificial Intelligence in Medicine consumption (value & volume) by key regions/countries, product type and application, history data. To understand the structure of the Artificial Intelligence in Medicine market by identifying its various sub-segments. Focuses on the key global Artificial Intelligence in Medicine manufacturers, to define, describe and analyze the sales volume, value, market share, market competitive landscape, SWOT analysis, and development plans in the next few years. To analyze the Artificial Intelligence in Medicine with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Go For Interesting Discount Here:http://bit.ly/2GpPkpU

Table of Content

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Artificial Intelligence in Medicine Market Size2.2 Artificial Intelligence in Medicine Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Artificial Intelligence in Medicine Market Size by Manufacturers3.2 Artificial Intelligence in Medicine Key Players Head office and Area Served3.3 Key Players Artificial Intelligence in Medicine Product/Solution/Service3.4 Date of Enter into Artificial Intelligence in Medicine Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Artificial Intelligence in Medicine Sales by Product4.2 Global Artificial Intelligence in Medicine Revenue by Product4.3 Artificial Intelligence in Medicine Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Artificial Intelligence in Medicine Breakdown Data by End User

Have any query? Inquiry about report at:http://bit.ly/2NX7xQ3

In the end, Artificial Intelligence in Medicine industry report specifics the major regions, market scenarios with the product price, volume, supply, revenue, production, and market growth rate, demand, forecast and so on. This report also presents SWOT analysis, investment feasibility analysis, and investment return analysis.

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us-Email:[emailprotected]Phone: + 91 8956767535Website:https://www.marketgrowthinsight.com

View original post here:
Artificial Intelligence in Medicine Market Advanced Technology and New Innovations by 2025 InSilico Medicine, Globavir Biosciences - PRnews Leader

OAKLAND, Calif.--(BUSINESS WIRE)--In a step toward the full realization of genomic medicine, Fabric Genomics, a leader in AI-based genomic analysis and interpretation, has announced a co-marketing agreement that will provide translational researchers around the world with integrated sample prep to reporting workflows. Combining Roches newly released KAPA HyperExome Probes (RUO) with the Fabric Enterprise bioinformatics and analysis platform will make genetic research faster, less costly and more accurate by providing an end-to-end solution from sample prep through analysis.

Fabric Genomics pioneered AI-driven genomic interpretation, and its Fabric Enterprise software platform for genomic data analysis and reporting is in use by clinical research laboratories, healthcare institutions and country sequencing programs around the world, including Rady Childrens Institute for Genomic Medicine, LabCorp and Genomics England. Last week Fabric Genomics released Fabric GEM, a novel algorithm that quickly identifies the likely genetic cause of rare diseases; the new technology is fully integrated within the Fabric Enterprise platform.

Roches exome sequencing workflow includes the KAPA HyperPrep and HyperPlus library preparation kits and exome probes, which allow users to quickly prepare samples for sequencing while delivering high on-target rates and 98% sensitivity for SNP detection.

In addition to improving turnaround times for genomic sequencing, the combination of these technologies will allow laboratories to increase automation and lower operational costs with improved scalability. Clinical research labs that are expanding assay menus will benefit from reduced costs of development and faster validation.

Clinical research labs have a need to take a collected sample from library prep quickly, all the way through to analysis, and our agreement with Roche demonstrates our commitment to supporting these critical workflows, said Martin Reese, PhD, co-founder and CEO of Fabric Genomics. Using our Fabric Enterprise analysis platform with Roche KAPA HyperExome Probes ensures high coverage of disease-causing genes, which is of the utmost importance in accelerating the identification of rare variants. Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based diagnostics in routine care. With widespread adoption of sequencing technology innovation, we can further our shared goal of improving personalized care.

KAPA products are for research use only (RUO). Not for use in diagnostic procedures.

About Fabric Genomics

Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics. Fabric Genomics is making genomics-driven precision medicine a reality. The company also provides clinical decision-support software that enables clinical labs, hospital systems and country sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabrics end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology.

To learn more, visit https://fabricgenomics.com/roche/ and follow us on Twitter and LinkedIn.

More:
Fabric Genomics to Co-market Comprehensive Sample-to-Genomic Analysis Sequencing Solutions for Hereditary Genetics - Business Wire

2020 has been a historical year from a variety of perspectives, and the stock market is no exception.

The year started off with a strong rally in many high-growth tech stocks, and expectations that global growth was starting to pick up after decelerating since 2018 due to the trade war.

As a result, the S&P 500 was trending higher, making new, all-time highs. However, this pretty picture was wrecked by the coronavirus which caused a 35% crash in stock prices in a little more than a month.

In turn, the Federal Reserve unleashed massive amounts of stimulus to support financial markets by cutting interest rates to zero and starting a bunch of programs to inject liquidity into various markets including corporate bonds. It doubled-down on its dovish stance by stating that interest rates will remain at zero until 2022 and adjusting its inflation framework to make clear to investors that interest rates wont increase until inflation meaningfully climbs above 2%. Previously, the Fed would begin to tighten in anticipation of interest rates hitting 2%.

There was similar aggression on the fiscal front. Due to the economic effects of the shutdown, Republicans and Democrats came together to pass a wide array of bills to boost unemployment checks, provide payroll support to businesses, and investments in health research. In total, this years deficit is expected to be $3.1 trillion due to a combination of lower tax revenue and increased expenditures.

However, this has undoubtedly had positive impacts on the economy as measures like consumer spending and housing have bounced back to levels higher than 2019. Other parts of the economy remain off levels from a year-ago but continue to show improvement on a month to month basis.

These factors also led to a V-shaped rebound in stock prices with the S&P 500 making new highs in August. Over the last two months, the markets momentum has stalled, and weve traded in a sideways range between 3,200 and 3,500.

Most likely, this is a healthy consolidation for the market. Overbought conditions are being relieved to set up the market for its next move higher. For investors who want to take advantage of this bull market and the recent dip, they should consider adding three ETFs with promising prospects into 2021: ARK Genomic Revolution Multi-Sector ETF (ARKG), Invesco Dynamic Leisure and Entertainment ETF (PEJ), and the Materials Select Sector SPDR ETF (XLB).

Reasons to Expect a Q4 Rally

All of these ETFs offer an intriguing upside. However, another important point is the overall trend in the general market, and investors should expect that stock prices will trend higher in the fourth quarter and through 2021. The best way to track the general market is through the SPDR S&P 500 ETF Trust (SPY).

The main factor is we had a major capitulation event in March 2020. Due to this and the economic uncertainty, there is a massive amount of money on the sidelines, specifically institutional funds. As this money is deployed, it will drive the market higher.

Weve seen previous major capitulatory events March 2009, May 2012, and February 2016 from those lows, prices kept moving higher and were strong in the following year. Its also not a coincidence that the Fed was also aggressively dovish during those periods like it is now.

In addition to the Fed, fiscal stimulus is also likely to be deployed if the economy starts to show signs of weakness. This also another reason to be supportive of the buy the dip trade. The polls also show a 65% chance that Joe Biden wins the Presidency and a 60% chance that Democrats win the Senate. This would increase the size and chances of stimulus being passed.

Another major catalyst for stock prices is that fund managers are underinvested and underexposed. The average fund is down around 7%, while the S&P 500 is up 5% YTD. The average fund manager is also underinvested in terms of stock exposure. Fund managers are assessed by how they perform relative to their benchmarks.

If they end the year underperforming by a significant margin, there is the chance that they will lose capital or their jobs. So, if stock prices keep creeping higher, many fund managers would be forced to buy, pushing shares up even more.

Of course, this dynamic is happening during a pretty bullish time seasonally. As the chart below shows, Q4 during a Presidential election year tends to be bullish. And, the gains could be particularly outsized this year if fund managers are piling in.

(source: LPL Financial)

ARK Genomic Revolution Multi-Sector ETF (ARKG)

While the markets are expected to move higher into Q4, investors should look at growth areas. Among these, biotechs are intriguing. The sector is benefiting from increased investment due to COVID-19, however, long-term fundamentals are solid due to the aging population and constant need for new treatments and therapies.

Additionally, the biotech sector has traded sideways for the last 5 years, while earnings have kept increasing, meaning that valuations are attractive. Within biotech, the most exciting area is genomics. ARKG is an ETF that gives diversified exposure to this group.

Genomics is in the early stages of transforming medicine. Currently, they are used more in diagnostics but scientists anticipate that they could be used in the future to repair cells at the cellular level and would lead to a future of personalized medicine. ARKG is a diversified way to take advantage of new development in medicine.

ARKG is rated a Buy according to the POWR Ratings. It has an A for Trade Grade and Industry Rank with a B for Buy & Hold Grade. Amongst Health & Biotech ETFs, its ranked #4 out of 38.

Invesco Dynamic Leisure and Entertainment ETF (PEJ)

PEJ is composed of a basket of restaurants, entertainment, and retail stocks. Whats interesting is that in recent months its shown signs of outperformance after underperforming for the duration of the rally. This is despite negative headlines with case counts rising and failure to reach agreement on a second stimulus deal.

The best trades come when sentiment is the most depressed. Currently, no sector is hated more than casinos, restaurants, and travel stocks. While many stocks made new highs since the March bottom, this group has massively underperformed.

Negative sentiment has increased in recent weeks as its clear that we are on the verge of a second wave: However, the data is also clear that deaths are not increasing as treatment has significantly improved. Many also believe that the prevalence of mask-wearing and social distancing means that viral loads are lower.

Additionally, TSA travel data, restaurant booking figures, and recent reports from casinos show that normalization is continuing. The world is going to return to normal at some point whether its in 2021 or 2022. Already, we are seeing a movement towards normalization despite case counts rising and no vaccine.

Materials Select Sector SPDR ETF (XLB)

Another interesting sector is materials stocks. For one, they have been in a downtrend since 2018, so they are interesting from a contrarian, value perspective. Additionally, one tailwind for the sector is that we are on the verge of a restocking cycle as inventories will need to be replenished as the world returns to normal.

Further, every government is using fiscal stimulus to combat the economic slowdown due to the coronavirus. This means more infrastructure projects. Already, we are seeing bullish price action in cyclical commodities like copper, iron ore, and lumber. All of these indicate that building activity and manufacturing will do well.

On a technical basis, XLB is outperforming on a shorter timeframe. If the virus gets worse to the extent that it will slow economic activity, then the sector will benefit from additional fiscal and monetary stimulus. If the recovery continues, then XLB will also do well due to the increased demand for materials.

According to the POWR Ratings, XLB is a Strong Buy, and it has an A for Trade Grade and Buy & Hold Grade. Among Industrial ETFs, its ranked #1 out of 33.

Want More Great Investing Ideas?

Top 11 Picks for Todays Market

Dangerous Outlook for Stocks Into Election

5 WINNING Stocks Chart Patterns

SPY shares fell $4.33 (-1.25%) in premarket trading Monday. Year-to-date, SPY has gained 8.97%, versus a % rise in the benchmark S&P 500 index during the same period.

Jaimini Desai has been a financial writer and reporter for nearly a decade. His goal is to help readers identify risks and opportunities in the markets. As a reporter, he covered the bond market, earnings, and economic data, publishing multiple times a day to readers all over the world. Learn more about Jaiminis background, along with links to his most recent articles. More...

Follow this link:
SPY: 3 ETFs That Could SOAR Into 2021 - StockNews.com

The research report on Age Related Macular Degeneration Biologic Drug Market gives thorough insights regarding various key trends that shape the industry expansion with regards to regional perspective and competitive spectrum. Furthermore, the document mentions the challenges and potential restrains along with latent opportunities which may positively impact the market outlook in existing and untapped business spaces. Moreover, it presents the case studies, including the ones related to COVID-19 pandemic, to convey better understanding of the industry to all the interested parties.

The recent market trend of increasingly using Age Related Macular Degeneration Biologic Drug for understanding the development of a disease extensively fuel the growth of this market in the coming years. Another trend that will aid the growth of the global Age Related Macular Degeneration Biologic Drug market is the escalating demand for personalized medicine. Extensive investments are being made by various organizations, pharmaceutical companies, and governments for the research and development of drugs, and this is another trend that is benefiting the growth of the global Age Related Macular Degeneration Biologic Drug market. This is because Age Related Macular Degeneration Biologic Drug techniques enable researchers to compare Age Related Macular Degeneration Biologic Drug changes between disease samples and normal samples. Public health can thus be analyzed as the changes in Age Related Macular Degeneration Biologic Drug are influenced by internal biological system and environment directly.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3927283?utm_source=Nilesh-TKC

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Regeneron, Valeant, Novartis, Genentech, Allergan, Eli Lilly, Alimera Sciences, Merck, Acucela, Bayer, Ophthotech Corporation.

Age Related Macular Degeneration Biologic Drug Market Segmentation:

In market segmentation by types of Age Related Macular Degeneration Biologic Drug, the report covers-

RanibizumabBevacizumabAflibercept

In market segmentation by applications of the Age Related Macular Degeneration Biologic Drug, the report covers the following uses-

Outpatient Surgery CenterEye ClinicHospital

Regional Analysis for Age Related Macular Degeneration Biologic Drug Market-:

1) North America- (United States, Canada)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)

3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)

4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)

5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru)

The report provides insights on the following pointers :

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

NOTE: Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3927283?utm_source=Nilesh-TKC

Table of Content

Chapter 1 Age Related Macular Degeneration Biologic Drug Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global Age Related Macular Degeneration Biologic Drug Market, by Type

Chapter 5 Age Related Macular Degeneration Biologic Drug Market, by Application

Chapter 6 Global Age Related Macular Degeneration Biologic Drug Market Analysis by Regions

Chapter 7 North America Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 8 Europe Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 9 Asia Pacific Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 10 Middle East and Africa Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 11 South America Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global Age Related Macular Degeneration Biologic Drug Market Forecast

Chapter 15 New Project Feasibility Analysis

Trending Market Research Reports :

COVID-19 Outbreak-Global Large Volume Wearable Injectors Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020: https://zenitnews.com/news/137473/large-volume-wearable-injectors-market-expert-guide-to-boost-the-industry-in-global-market-share/

COVID-19 Outbreak-Global Malaria Diagnostics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020: https://eurowire.co/coronavirus/501431/malaria-diagnostics-industry-global-market-trend-share-profit-growth-and-key-manufacturers-analysis-report/

2020-2025 Global and Regional Web Server Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report: https://rejerusalem.com/190476/web-server-market-size-share-trend-analysis-growth-factor-and-analysis-by-its-key-vendors-2025/

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Mr. Abhishek Paliwal

Big Market Research

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: [emailprotected]

Visit link:
Most recent development report on Age Related Macular Degeneration Biologic Drug Market to Witness Exponential Rise in Revenue Share during the...

WASHINGTON, Oct. 26, 2020 /PRNewswire/ --Despite the increasing use and promise of hematopoietic cell transplantation (HCT) as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children transplanted for cancer are more likely to die from treatment-related complications if they live in poorer neighborhoods. The study, published today in the journal Blood, also found that having Medicaid versus private insurance, another marker of poverty, was associated with a higher chance of dying. Researchers say the results underscore the need to better understand and mitigate the effects of poverty and other social determinants of health on pediatric cancer care.

Hematopoietic cell transplantation, also called stem cell or bone marrow transplantation, is a treatment option for patients with blood cancers such as leukemia or lymphoma, as well as certain non-malignant conditions such as sickle cell disease or immunodeficiencies. It is only accessible at some medical centers. Together with radiation therapy or chemotherapy, HCT is designed to increase the chance of eliminating the cancerous or abnormal blood cells, and of restoring normal blood cell production.

The data revealed that children under the age of 18 with cancer who live in communities with high poverty rates had a 34% greater risk of treatment-related mortality following HCT compared with children in low-poverty areas. Even after adjusting for a child's disease and transplant-related factors, the data revealed children on Medicaid had a 23% greater risk of dying from any cause within five years of undergoing HCT and a 28% greater risk of treatment-related mortality when compared to children with private insurance.

"Our study shows that even after children with cancer have successfully accessed this high-resource treatment at specialized medical centers, those who are exposed to poverty are still at higher risk of dying of complications after treatment and of dying overall," said lead author Kira Bona, MD, MPH, Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. "Simply providing the highest quality complex medical care to children who are vulnerable from a social perspective is inadequate if our goal is to cure every child with cancer."

One in five children in the U.S. lives in a household with an income below the federal poverty level. While previous studies have shown an association between household poverty and poorer outcomes in HCT procedures generally, there are limited data on how poverty influences the success of HCT in children specifically.

Dr. Bona and her team sought to fill this gap by reviewing outcomes data for pediatric allogeneic transplant recipients from the Center for International Blood and Marrow Transplant Research Database, the largest available repository of HCT outcomes. The researchers looked at two cohorts of patients: 2,053 children with malignant disease and 1,696 children with non-malignant disease, who underwent a first HCT between 2006 and 2015. Neighborhood poverty exposure was defined according to U.S. Census definitions as living within a ZIP code in which 20% or more of the residents live below 100% of the Federal Poverty Level. They also stratified patients by type of insurance and used Medicaid as a proxy measure for household level poverty. The researchers looked at pediatric patients' overall survival defined as the time from HCT until death from any cause, as well as relapse, transplant-related mortality, acute and chronic graft-versus-host disease, and infection in the first 100 days following HCT.

Interestingly, neighborhood poverty or having Medicaid insurance did not seem to affect outcomes, including overall survival, relapse, or infection, among children transplanted for non-malignant diseases such as sickle cell disease. Dr. Bona said the study does not explain why this might be and more research is needed; however, it is possible that physicians and families of children with non-malignant conditions who face social health challenges may elect to avoid intensive HCT procedures.

One study limitation is its reliance on proxy measures of household poverty (ZIP code and Medicaid insurance) that do not provide insight into specific aspects of an individual child's socioeconomic exposures and the home environment in which they live that may interfere with their ability to navigate the health care system. Dr. Bona says researchers and clinicians have historically not considered social determinants of health as being as important as biological variables in specialized cancer care and so have not collected data on these factors as part of research. She says this is a missed opportunity.

"We as a field need to recognize that non-biological variables such as your exposure to poverty and other social determinants of health matter just as much as many of the biological variables we pay close attention to when thinking about outcomes for children, and these variables must be collected systematically for research if we want to optimize the care and outcomes of the children we serve," Dr. Bona said.

If future studies could collect more nuanced measures of poverty such as household material hardship (e.g., food insecurity, access to heat and electricity, housing insecurity, transportation insecurity) or language barriers, targeted interventions in the form of assistance programs could potentially help mitigate social hardships and improve the overall care of children with cancer.

Blood(www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).

SOURCE American Society of Hematology/Blood Journal

http://www.bloodjournal.org

Continue reading here:
Study: Poverty Linked to Higher Risk of Death Among Children with Cancer Undergoing Stem Cell Transplantation - PRNewswire